Gene therapy for vein graft failure

Journal of Cardiac Surgery

Volumn 28, Issue 2, 2013, Pages 144-147

  Wang, Xiao Wen ^a   Zhao, Xing Ji ^b   Xiang, Xiao Yong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING EMERGENCY MEDICAL CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; EDIFOLIGIDE; KRUPPEL LIKE FACTOR 4; MICRORNA 143; MICRORNA 145; OLIGODEOXYNUCLEOTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VIRUS VECTOR;

ATHEROMA; ATHEROSCLEROSIS; GENE THERAPY; GRAFT FAILURE; HUMAN; HYPERPLASIA; NEOINTIMA; PATHOGENESIS; RESTENOSIS; REVIEW; THROMBOSIS; VEIN GRAFT; VEIN GRAFT DISEASE; VEIN GRAFT RESTENOSIS;

CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; GENETIC THERAPY; HUMANS; NEOINTIMA; PLAQUE, ATHEROSCLEROTIC; SAPHENOUS VEIN; THROMBOSIS;

EID: 84875226777     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/jocs.12075     Document Type: Review

References (53)

1. Graham MM, Ghali WA, Faris PD, et al. Survival after coronary revascularization in the elderly. Circulation 2002; 105: 2378-2384.
2. Hata M, Sezai A, Niino T, et al. What is the optimal management for preventing saphenous vein graft diseases? Early results of intravascular angioscopic assessment. Circ J 2007; 71: 286-287.
3. Solymoss BC, Nadeau P, Millette D, et al. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988; 78: I140-I143.
4. Muto A, Model L, Ziegler K, et al. Mechanisms of vein graft adaptation to the arterial circulation: Insights into the neointimal algorithm and management strategies. Circ J 2010; 74: 1501-1512.
5. Kalan JM, Roberts WC:, Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: Necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am Heart J 1990; 119: 1164-1184.
6. Motwani JG, Topol EJ:, Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916-931.
7. Bhardwaj S, Roy H, Yla-Herttuala S:, Gene therapy to prevent occlusion of venous bypass grafts. Expert Rev Cardiovasc Ther 2008; 6: 641-652.
8. Hassantash SA, Bikdeli B, Kalantarian S, et al. Pathophysiology of aortocoronary saphenous vein bypass graft disease. Asian Cardiovasc Thorac Ann 2008; 16: 331-336.
9. Peykar S, Angiolillo DJ, Bass TA, et al. Saphenous vein graft disease. Minerva Cardioangiol 2004; 52: 379-390.
10. Allaire E, Clowes AW:, Endothelial cell injury in cardiovascular surgery: The intimal hyperplastic response. Ann Thorac Surg 1997; 63: 582-591.
11. Kauhanen P, Siren V, Carpen O, et al. Plasminogen activator inhibitor-1 in neointima of vein grafts: Its role in reduced fibrinolytic potential and graft failure. Circulation 1997; 96: 1783-1789.
12. Domanski MJ, Borkowf CB, Campeau L, et al. Prognostic factors for atherosclerosis progression in saphenous vein grafts: The postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. J Am Coll Cardiol 2000; 36: 1877-1883.
13. Bhardwaj S, Roy H, Heikura T, et al. VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur J Clin Invest 2005; 35: 669-676.
14. Donetti E, Baetta R, Comparato C, et al. Polymorphonuclear leukocyte-myocyte interaction: An early event in collar-induced rabbit carotid intimal thickening. Exp Cell Res 2002; 274: 197-206.
15. Amano J, Suzuki A, Sunamori M, et al. Cytokinetic study of aortocoronary bypass vein grafts in place for less than six months. Am J Cardiol 1991; 67: 1234-1236.
16. Dietrich H, Hu Y, Zou Y, et al. Rapid development of vein graft atheroma in ApoE-deficient mice. Am J Pathol 2000; 157: 659-669.
17. Kockx MM, Cambier BA, Bortier HE, et al. Foam cell replication and smooth muscle cell apoptosis in human saphenous vein grafts. Histopathology 1994; 25: 365-371.
18. Cooney R, Hynes SO, Sharif F, et al. Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury. Gene Ther 2007; 14: 396-404.
19. Akowuah EF, Gray C, Lawrie A, et al. Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. Gene Ther 2005; 12: 1154-1157.
20. West NE, Qian H, Guzik TJ, et al. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: Effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 2001; 104: 1526-1532.
21. Mayr U, Mayr M, Li C, et al. Loss of p53 accelerates neointimal lesions of vein bypass grafts in mice. Circ Res 2002; 90: 197-204.
22. Wan S, George SJ, Nicklin SA, et al. Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004; 9: 689-698.
23. Petrofski JA, Hata JA, Gehrig TR, et al. Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia. J Thorac Cardiovasc Surg 2004; 127: 27-33.
24. Wolff RA, Ryomoto M, Stark VE, et al. Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. J Vasc Surg 2005; 41: 498-508.
25. Ehsan A, Mann MJ, Dell'Acqua G, et al. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121: 714-722.
26. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
27. Alexander JH, Ferguson TB, Jr., Joseph DM, et al. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: Study rationale, design, and baseline patient characteristics. Am Heart J 2005; 150: 643-649.
28. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA 2005; 294: 2446-2454.
29. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006; 43: 742-751, discussion 751.
30. Lopes RD, Williams JB, Mehta RH, et al. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J 2012; 164: 379-386, e371.
31. Bartel DP:, MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
32. Eulalio A, Huntzinger E, Izaurralde E:, Getting to the root of miRNA-mediated gene silencing. Cell 2008; 132: 9-14.
33. Filipowicz W, Bhattacharyya SN, Sonenberg N:, Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight ? Nat Rev Genet 2008; 9: 102-114.
34. He L, Hannon GJ:, MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
35. Small EM, Frost RJ, Olson EN:, MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010; 121: 1022-1032.
36. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100: 1579-1588.
37. Zhang C:, MicroRNAs: Role in cardiovascular biology and disease. Clin Sci Lond 2008; 114: 699-706.
38. Qin S, Zhang C:, MicroRNAs in vascular disease. J Cardiovasc Pharmacol 2011; 57: 8-12.
39. Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009; 105: 158-166.
40. Liu X, Cheng Y, Zhang S, et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009; 104: 476-487.
41. Boettger T, Beetz N, Kostin S, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009; 119: 2634-2647.
42. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460: 705-710.
43. Zhang C:, MicroRNA-145 in vascular smooth muscle cell biology: A new therapeutic target for vascular disease. Cell Cycle 2009; 8: 3469-3473.
44. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: Correlates with human disease. Cell Death Differ 2009; 16: 1590-1598.
45. Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009; 23: 2166-2178.
46. Boucher JM, Peterson SM, Urs S, et al. The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells. J Biol Chem 2011; 286: 28312-28321.
47. Lovren F, Pan Y, Quan A, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012; 126: S81-S90.
48. Davies MG, Hagen PO:, Pathobiology of intimal hyperplasia. Br J Surg 1994; 81: 1254-1269.
49. Xu Q, Zhang Z, Davison F, et al. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. Circ Res 2003; 93: e76-e86.
50. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-438.
51. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
52. Wang CH, Anderson N, Li SH, et al. Stem cell factor deficiency is vasculoprotective: Unraveling a new therapeutic potential of imatinib mesylate. Circ Res 2006; 99: 617-625.
53. Xu Q:, Stem cells and transplant arteriosclerosis. Circ Res 2008; 102: 1011-1024.